CDC STACKS serves as an archival repository of CDC-published products including scientific findings, journal articles, guidelines, recommendations, or other public health information authored or co-authored by CDC or funded partners.
As a repository, CDC STACKS retains documents in their original published format to ensure public access to scientific information.
i
Use of weight loss medications in relation with prostate, colorectal and male breast cancers among older men: SEER-Medicare 2007–2015
-
9 2023
-
-
Source: J Cancer Res Clin Oncol. 149(11):8255-8265
[PDF-560.89 KB]
Details:
-
Alternative Title:J Cancer Res Clin Oncol
-
Personal Author:
-
Description:Background
The association of weight loss medications with prostate (PCa), colorectal (CRC) or male breast cancers, including assessment of these cancers combined (HRCs, hormone-associated cancers) remain poorly understood. Testosterone replacement therapy (TTh) is reported to be inversely associated with obesity, PCa and CRC, but it is unclear whether TTh modifies the association of weight loss medications with HRCs.
Methods
In 49,038 men (≥ 65 years) of SEER-Medicare, we identified 15,471 men diagnosed with PCa, 4836 with CRC, and 141 with male breast cancers. Pre-diagnostic prescription of weight loss medications and TTh was ascertained for this analysis. Weighted multivariable-adjusted conditional logistic and Cox proportional hazards (mortality) models were conducted.
Results
We found an inverse association between use of weight loss medications and incident PCa (OR 0.59, 95% CI 0.57–0.62), CRC (OR 0.86, 95% CI 0.80–0.92), and HRCs (OR 0.65, 95% CI 0.62–0.68). Similar associations were observed for advanced stage at diagnosis of PCa and CRC. Effects of weight loss medications on PCa and HRC remained significant irrespective of the use of TTh but were only suggestive with CRC with positive TTh use. No associations were observed with male breast cancer and HRCs mortality.
Conclusion
Pre-diagnostic use of weight loss medications reduced the incidence of PCa, CRC, and HRCs. These associations persisted in the same direction irrespective of the history of TTh use. Future studies are needed to confirm these findings and to identify underlying biological mechanisms of weight loss medications and TTh on the risk of cancer.
-
Subjects:
-
Keywords:
-
Source:
-
Pubmed ID:37067547
-
Pubmed Central ID:PMC10702173
-
Document Type:
-
Funding:
-
Volume:149
-
Issue:11
-
Collection(s):
-
Main Document Checksum:
-
Download URL:
-
File Type:
